secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-05-23T23:59:59+00:00
Accession:  0000875320-22-000017
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Pharmaceuticals acquires Catalyst Biosciences' complement portfolio for $60 million
--------------------------------------------------------------------------------

- Vertex acquired Catalyst's complement portfolio and related IP, including CB 2782-PEG, for $60 million cash.
- The transaction closed on May 19, 2022, and was disclosed in an 8-K filed May 23, 2022.
- Vertex will record the $60 million purchase price in GAAP and non-GAAP operating expenses in Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000017/0000875320-22-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000017/vrtx-20220523.htm
  HTML page:      https://secwatch.observer/filing/0000875320-22-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer